About

Seres Therapeutics specializes in developing microbiome therapeutics, including the first orally administered microbiota-based therapeutic, VOWST™, aimed at preventing C. difficile infection recurrence in adults. They also focus on SER-155 for reducing gastrointestinal infections and research microbiome therapeutics for ulcerative colitis, utilizing microbiome-based treatments and orally administered microbiota-based therapies.